BIVI - BIVI INVESTORS: Lead Plaintiff is Quickly Approaching; Contact Robbins LLP for Information About Your Rights | Benzinga
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioVie (NASDAQ:BIVI) securities between August 5, 2021 and November 29, 2023. BioVie is a clinical stage biopharmaceutical company that purports to engage in the discovery, development, and commercialization of innovative drugs therapies, including for treatment of neurological and neurodegenerative disorders and advanced liver disease.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: BioVie Inc. (BIVI) Allegedly Failed to Disclose Scientific Misconduct in Connection with its Clinical Trial
According to the complaint, on August 5, 2021, BioVie announced enrollment of the first patient in its Phase 3 study of NE3107 in Alzheimer's Disease. On November 29, 2023, defendants reported that the Phase 3 clinical trial "did not achieve statistical significance because we had to exclude so many patients from the trials that we believe engaged in improper practices." Defendants further noted that BioVie had to exclude 358 patients, which represented "over 80% of our enrolled populations due to suspected improper conduct at 15 clinical ...